Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial
Wieneke, H.; Conrads, H.; Wolstein, Jörg; u. a. (2009): Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial, in: European Journal of Medical Research, London: BioMed Central, Jg. 14, Nr. 7, S. 7–12, doi: 10.1186/2047-783X-14-1-7.
Details
- Fakultät/Lehrstuhl
- Autorin(nen)/Autor(en)
- Wieneke, H.Conrads, H.Breuckmann, F.Gastpar, M.Erbel, R.Scherbaum, N.
- Titel der Zeitschrift
- European Journal of Medical Research
- Herausgebende Institution
- Deutsche AIDS-Gesellschaft
- Verlagsangabe
- BioMed Central : London
- Erscheinungsjahr
- 2009
- Jahrgang
- 14
- Heft
- 7
- Sprache(n)
- Englisch
- DOI
- Abstract
Background
Due to potential proarrhythmic side-effects levo-α-Acetylmethadol (LAAM) is currently not available in EU countries as maintenance drug in the treatment of opiate addiction. However, recent studies and meta-analyses underline the clinical advantages of LAAM with respect to the reduction of heroin use. Thus a reappraisal of LAAM has been demanded. The aim of the present study was to evaluate the relative impact of LAAM on QTc-interval, as a measure of pro-arrhythmic risk, in comparison to methadone, the current standard in substitution therapy.
Methods
ECG recordings were analysed within a randomized, controlled clinical trial evaluating the efficacy and tolerability of maintenance treatment with LAAM compared with racemic methadone. Recordings were done at two points: 1) during a run-in period with all patients on methadone and 2) 24 weeks after randomisation into methadone or LAAM treatment group. These ECG recordings were analysed with respect to QTc-values and QTc-dispersion. Mean values as well as individual changes compared to baseline parameters were evaluated. QTc-intervals were classified according to CPMP-guidelines.
Results
Complete ECG data sets could be obtained in 53 patients (31 LAAM-group, 22 methadone-group). No clinical cardiac complications were observed in either group. After 24 weeks, patients receiving LAAM showed a significant increase in QTc-interval (0.409 s ± 0.022 s versus 0.418 s ± 0.028 s, p = 0.046), whereas no significant changes could be observed in patients remaining on methadone. There was no statistically significant change in QTc-dispersion in either group. More patients with borderline prolonged and prolonged QTc-intervals were observed in the LAAM than in the methadone treatment group (n = 7 vs. n = 1; p = 0.1).
Conclusions
In this controlled trial LAAM induced QTc-prolongation in a higher degree than methadone. Given reports of severe arrhythmic events, careful ECG-monitoring is recommended under LAAM medication.
- Freie Schlagwort(e)
- LAAMmethadoneopiate addictioncardiac arrhythmiaQTc-interval
- Open-Access-Zeitschrift
- nein
- Dokumenttyp
- Artikel in einer Zeitschrift / Postprint
- URI
- Datum der Freischaltung
- 23.11.2018, 23.11.2018